Flexion Therapeutics Named one of Boston Business Journal’s Best Places to Work for the Third Consecutive Year
June 20 2019 - 9:00AM
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it
has been named one of Boston Business Journal’s “Best Places to
Work” for the third consecutive year. Flexion was the only
Boston-area biopharmaceutical company recognized in the medium
business category (100 to 249 employees).
“There is tremendous competition for talent in the biotech
industry, and awards like this differentiate Flexion and give us an
advantage when it comes to attracting and retaining top talent,”
said Michael Clayman, M.D., President and Chief Executive Officer
of Flexion. “We are extraordinarily grateful to our employees whose
commitment allows us to make a meaningful difference in the lives
of our patients.”
The “Best Places to Work” Program recognizes companies within
the greater Boston area that embody strong company culture and
create an exceptional work environment for their employees. This
year Boston Business Journal recognized 79 local employers which
are divided into categories based on company size. The rankings are
determined by employees’ responses to survey questions which focus
on communication and resources, individual needs, manager
effectiveness, personal engagement, team dynamics and trust in
leadership.
About Flexion Therapeutics
Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical
company focused on the development and commercialization of novel,
local therapies for the treatment of patients with musculoskeletal
conditions, beginning with osteoarthritis, a type of degenerative
arthritis. The company's core values are focus, ingenuity,
tenacity, transparency and fun. For the past three years, Flexion
has been named one of the Best Places to Work by the Boston
Business Journal, and Flexion was also recognized as a Top Place to
Work in Massachusetts by The Boston Globe in 2017 and 2018.
Contacts:
Julie DownsManager, Corporate CommunicationsFlexion
Therapeutics, Inc. T:
781-305-7137jdowns@flexiontherapeutics.com
Laurel Orcutt Intern, Corporate CommunicationsFlexion
Therapeutics, Inc. T: 781-305-7554
lorcutt@flexiontherapeutics.com
Flexion Therapeutics (NASDAQ:FLXN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Flexion Therapeutics (NASDAQ:FLXN)
Historical Stock Chart
From Apr 2023 to Apr 2024